Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Xtandi
| Field | Information |
|---|---|
| Medication Name | Xtandi |
| Generic Name | Enzalutamide |
| Boxed/Label Warning | Seizure Risk; Posterior Reversible Encephalopathy Syndrome (PRES) |
| Purpose | Treatment of metastatic castration-resistant prostate cancer (mCRPC) and castration-sensitive prostate cancer. |
| Mechanism of Action | Androgen receptor inhibitor that blocks the binding of androgens, preventing androgen receptor translocation and DNA binding. |
| Dosage Forms | Oral capsules |
| Available Strengths | 40 mg |
| Dosage Frequency | Once daily |
| Common Side Effects | Fatigue, hot flashes, hypertension, musculoskeletal pain, diarrhea, asthenia, falls. |
| Serious Side Effects | Seizures, posterior reversible encephalopathy syndrome (PRES), ischemic heart disease, falls and fractures, hypersensitivity. |
| Drug Interactions | Strong CYP2C8 inhibitors (e.g., gemfibrozil), strong CYP3A4 inducers (e.g., rifampin), CYP2C9 substrates (e.g., warfarin). |
| Important Notes | Monitor for seizures, hypertension, and falls. Avoid driving or operating heavy machinery if prone to these side effects. Consult your doctor if you experience any neurological symptoms. |
| Storage | Store at room temperature between 68°F to 77°F (20°C to 25°C). Protect from moisture. |
| Missed Dose | Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not double the dose. |
| Alternatives | Zytiga (abiraterone), Erleada (apalutamide), Nubeqa (darolutamide), Jevtana (cabazitaxel). |
Xtandi Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Zytiga (abiraterone) | Inhibits CYP17A1, reducing androgen production. | Taken with prednisone. |
| Erleada (apalutamide) | Androgen receptor inhibitor | Used for non-metastatic and metastatic castration-resistant prostate cancer. |
| Nubeqa (darolutamide) | Androgen receptor inhibitor | Used for non-metastatic castration-resistant prostate cancer. |
| Jevtana (cabazitaxel) | Microtubule inhibitor | Chemotherapy agent used after docetaxel failure. |
Xtandi Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Fatigue | Seizures |
| Hot flashes | Posterior Reversible Encephalopathy Syndrome (PRES) |
| Hypertension | Ischemic heart disease |
| Musculoskeletal pain | Falls and fractures |
| Diarrhea | Hypersensitivity reactions (rash, angioedema) |
Xtandi Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 160 mg | 160 mg once daily | Take orally with or without food. |
| Castration-Sensitive Prostate Cancer | 160 mg | 160 mg once daily | Take orally with or without food. Continue androgen deprivation therapy (ADT). |
Xtandi Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $0 – $100 |
| Without Insurance (U.S.) | $14,900 |
| From Canada | $4,789 |
